



Express Mail No: EL 500 576 454 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al.

Confirmation No.: 1802

Application No.: 09/873,403

Group Art Unit: 1642

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For: COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR IMMUNOTHERAPY

Attorney Docket No.: 8449-178-999

RECEIVED

FEE TRANSMITTAL SHEET

OCT 28 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.

The claim amendment fee has been estimated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY		
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE
TOTAL 13	MINUS 26	= 0	× 9	\$ 0.00	× 18	\$	
INDEP. 4	MINUS 13	= 0	× 42	\$ 0.00	× 84	\$	
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			140	\$	280	\$	
			TOTAL	\$ 0.00	OR	TOTAL	\$

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.
A copy of this sheet is enclosed.

Respectfully submitted,

Date: October 23, 2002

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

By: Eileen E. Falvey 46,097
Eileen E. Falvey (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090



RECEIVED

OCT 28 2002

TECH CENTER 1600/2900

1542

Express Mail No: EL 500 576 454 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al.

Confirmation No.: 1802

Application No.: 09/873,403

Group Art Unit: 1642

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For: COMPLEXES OF ALPHA (2)
MACROGLOBULIN AND ANTIGENIC
MOLECULES FOR IMMUNOTHERAPY

Attorney Docket No.: 8449-178-999

PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115 AND
RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 C.F.R. § 1.142

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated September 23, 2002, and pursuant to Rules 115 and 142 of the Rules of Practice, please enter the following amendments and consider the remarks below. Applicants submit concurrently herewith: (1) Exhibit A: a marked-up version of the claims showing the amendments made herein; (2) Exhibit B: the claims that will pending upon entry of the amendments made herein; (3) an Amendment Fee Transmittal Sheet; (4) a Supplemental Information Disclosure Statement; (5) List of References Cited by Applicant; and (6) a copies of references EA-EB.

IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims 5, 6, 10-29, and 30-36 without prejudice.

Please amend claims 1, 3, and 7 to read as follows:

1. (amended) A pharmaceutical composition comprising an amount of a purified molecular complex effective for treatment or prevention of an infectious disease or a proliferative disorder, and a pharmaceutically acceptable carrier, said molecular complex